Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2023-08-29 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于回购并注销2021年限制性股票激励计划已离职激励对象已获授但尚未解除限售部分限制性股票的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the repurchase and cancellation of restricted shares under the 2021 restricted stock incentive plan for employees who have left the company. It details the number of shares repurchased, the price, the approval process, and the impact on the company's share capital structure. The document includes legal opinions, independent director opinions, and supervisory board opinions, all related to the repurchase and cancellation of shares. This is a corporate announcement about a transaction involving the company's own shares (repurchase and cancellation of restricted stock). It is not a financial report, earnings release, or management discussion. It fits the category of "Transaction in Own Shares" (POS), which covers share repurchase or issuance announcements. The document length is over 5,000 characters and contains detailed information about the transaction, not just a brief notice or a report publication announcement.
2023-08-29 Chinese
昆药集团关于2023年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a special report on the storage and actual use of raised funds for the half-year period ending June 30, 2023. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding the management and use of raised funds. The content details the amounts raised through various stock issuances (initial public offering, additional issuance, and private placement), the use of these funds, the management system for the funds, and the investment projects funded by these raised funds. It also includes detailed tables of fund usage, investment projects, and cash management of idle raised funds. The document is a comprehensive report on the fundraising activities and the actual use of the raised capital for a specific interim period (half-year 2023). This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an announcement of a report but a detailed report itself, and it is not a general regulatory filing or a report publication announcement. Therefore, the correct classification is CAP with high confidence.
2023-08-29 Chinese
昆药集团2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2023 年半年度报告" which translates to "2023 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, company overview, industry analysis, and operational performance for the first half of 2023. The document is lengthy (15,000 characters) and includes comprehensive financial statements and analysis, not just an announcement or summary. The presence of sections like "管理层讨论与分析" (Management Discussion and Analysis) and detailed financial metrics confirms it is a substantive interim financial report. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-29 Chinese
昆药集团十届十七次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kunming Pharmaceutical Group Co., Ltd. It details the approval of the company's 2023 half-year report and related matters such as asset impairment provisions, fundraising usage, stock repurchase, and accounting policy changes. The document does not contain the actual half-year financial report or detailed financial statements but rather the Supervisory Board's approval and opinions on these matters. It also references other announcements and reports published elsewhere. The document length is short (1547 characters) and primarily serves as an official announcement of board resolutions rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and board supervisory resolution notice, not as the interim report (IR) or annual report (10-K).
2023-08-29 Chinese
昆药集团关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding a change in accounting policies. It references specific accounting standards and interpretations issued by the Ministry of Finance in China, detailing the nature and impact of the accounting policy changes. The document includes statements from the board of directors, independent directors, and the supervisory board confirming the legitimacy and compliance of the changes. The document length is 2846 characters, which is relatively short and primarily serves as an announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it is not an Annual Report (10-K), Interim Report (IR), or Management Report (MDA). It is also not a certification or officer attestation document. The content fits best with a Regulatory Filing (RNS) as it is a formal regulatory announcement about accounting policy changes without full financial data or report content.
2023-08-29 Chinese
昆药集团股东集中竞价减持股份结果公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the results of a shareholder's share reduction (shareholding decrease) through centralized bidding. It details the shareholder's initial holdings, the planned reduction, the actual shares reduced, and the completion status of the reduction plan. There is no financial report, earnings data, or management discussion. The content fits the category of a Major Shareholding Notification, specifically reporting a change in significant share ownership levels. The document length is short and focused on shareholding changes, not a full report or announcement of a report publication. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2023-08-04 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.